Skip to main content
SpringerLink
Log in

Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia

  • Original Article
  • Published:
Brain Structure and Function Aims and scope Submit manuscript

Abstract

Previous work from our laboratory showed deficits in tyrosine hydroxylase protein expression within the substantia nigra/ventral tegmental area (SN/VTA) in schizophrenia. However, little is known about the nature and specific location of these deficits within the SN/VTA. The present study had two aims: (1) test if tyrosine hydroxylase deficits could be explained as the result of neuronal loss; (2) assess if deficits in tyrosine hydroxylase are sub-region specific within the SN/VTA, and thus, could affect specific dopaminergic pathways. To achieve these objectives: (1) we obtained estimates of the number of dopaminergic neurons, total number of neurons, and their ratio in matched SN/VTA schizophrenia and control samples; (2) we performed a qualitative assessment in SN/VTA schizophrenia and control matched samples that were processed simultaneously for tyrosine hydroxylase immunohistochemistry. We did not find any significant differences in the total number of neurons, dopaminergic neurons, or their ratio. Our qualitative study of TH expression showed a conspicuous decrease in labeling of neuronal processes and cell bodies within the SN/VTA, which was sub-region specific. Dorsal diencephalic dopaminergic populations of the SN/VTA presented the most conspicuous decrease in TH labeling. These data support the existence of pathway-specific dopaminergic deficits that would affect the dopamine input to the cortex without significant neuronal loss. Interestingly, these findings support earlier reports of decreases in tyrosine hydroxylase labeling in the target areas for this dopaminergic input in the prefrontal and entorhinal cortex. Finally, our findings support that tyrosine hydroxylase deficits could contribute to the hypodopaminergic state observed in cortical areas in schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Abi-Dargham A, Silstein M, Kegeles L, Laruelle M (2010) Dopamine dysfunction in schizophrenia. In: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A (eds) Dopamine Handbook. Oxford University Press, Oxford, pp 511–519

    Google Scholar 

  • Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA (1999) Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156:1580–1589

    Article  CAS  PubMed  Google Scholar 

  • Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA (2000) Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol Psychiatry 47:361–370

    Article  CAS  PubMed  Google Scholar 

  • Bergman O, Hakansson A, Westberg L, Nordenstrom K, Carmine Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H (2010) PITX3 polymorphism is associated with early onset Parkinson’s disease. Neurobiol Aging 31:114–117

    Article  CAS  PubMed  Google Scholar 

  • Bogerts B, Hantsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiatry 18:951–969

    CAS  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20:140–144

    Article  CAS  Google Scholar 

  • Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200

    Article  CAS  PubMed  Google Scholar 

  • Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709–1725

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Article  CAS  PubMed  Google Scholar 

  • Damier P, Hirsch EC, Agid Y, Graybiel AM (1999a) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28 K) immunohistochemistry. Brain 122:1421–1436

    Article  PubMed  Google Scholar 

  • Damier P, Hirsch EC, Agid Y, Graybiel AM (1999b) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122:1437–1448

    Article  PubMed  Google Scholar 

  • Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486

    Article  CAS  PubMed  Google Scholar 

  • Fallon JH, Loughlin SE (1987) Monoamine innervation of cerebral cortex and a theory of the role of monoamines in cerebral cortex and basal ganglia. In: Jones EG, Peters A (eds) cerebral cortex. Plenum Press, New York, pp 41–109

    Google Scholar 

  • Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301

    Article  PubMed  Google Scholar 

  • Finlay JM (2001) Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 27:431–442

    Article  CAS  PubMed  Google Scholar 

  • Floresco SB, Magyar O (2006) Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 188:567–585

    Article  CAS  PubMed  Google Scholar 

  • Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16:437–446

    Article  CAS  PubMed  Google Scholar 

  • Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wullner U, Illig T, Sharma M, Gasser T (2009) The transcription factor PITX3 is associated with sporadic Parkinson’s disease. Neurobiol Aging 30:731–738

    Article  CAS  PubMed  Google Scholar 

  • Gaspar P, Stepniewska I, Kaas JH (1992) Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol 325:1–21

    Article  CAS  PubMed  Google Scholar 

  • Gibb WR, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 54:388–396

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Goldman-Rakic PS (1996) Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93:13473–13480

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Grimm J, Mueller A, Hefti F, Rosenthal A (2004) Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci USA 101:13891–13896

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Grunblatt E, Mandel S, Maor G, Youdim MB (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson’s disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78:1–12

    Article  CAS  PubMed  Google Scholar 

  • Guillin O, Abi-Dargham A, Laurelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1–39

    Article  CAS  PubMed  Google Scholar 

  • Haber SN, Fudge JL (1997) The primate substantia nigra and VTA: integrative circuitry and function. Crit Rev Neurobiol 11:323–342

    Article  CAS  PubMed  Google Scholar 

  • Haber SN, Gdowski MJ (2004) The basal ganglia. In: Paxinos G, Mai JK (eds) The Human Nervous System. Elsevier Academic Press, London, pp 676–738

    Chapter  Google Scholar 

  • Haber SN, Ryoo H, Cox C, Lu W (1995) Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362:400–410

    Article  CAS  PubMed  Google Scholar 

  • Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, Vance JM (2005) Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62:917–921

    Article  PubMed  Google Scholar 

  • Hirsch E, Graybiel AM, Agid AM (1988) Melanized dopaminergic neurons are differentially susceptible to degradation in Parkinson’s disease. Nature 334:345–348

    Article  CAS  PubMed  Google Scholar 

  • Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 35:549–562

    Article  PubMed Central  PubMed  Google Scholar 

  • Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, Turkheimer F (2013) Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 136:3242–3251

    Article  PubMed Central  PubMed  Google Scholar 

  • Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic l-aminoacid decarboxylase in the substantia nigra in Parkinson’s disease and schizophrenia. J Neural Transm Park Dis Dement Sect 8:149–158

    Article  CAS  PubMed  Google Scholar 

  • Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A, Herman MM, Hyde TM, Winberger DR, Lipska BK, Kleinman JE (2013) Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia. Mol Psychiatry. doi:10.1038/mp.2013.165

    PubMed  Google Scholar 

  • Keshavan MS, Nasrallah HA, Tandon R (2011) Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res 127:3–13

    Article  PubMed Central  PubMed  Google Scholar 

  • Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123:366–373

    Article  PubMed  Google Scholar 

  • Lopez-Garcia P, Young Espinoza L, Molero Santos P, Marin J, Ortuno Sanchez-Pedreno F (2013) Impact of COMT genotype on cognition in schizophrenia spectrum patients and their relatives. Psychiatry Res 208:118–124

    Article  CAS  PubMed  Google Scholar 

  • Luk KC, Rymar VV, van den Munckhof P, Nicolau S, Steriade C, Bifsha P, Drouin J, Sadikot AF (2013) The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. J Neurochem 125:932–943

    Article  CAS  PubMed  Google Scholar 

  • Meyer-Lindenberg A (2010) Imaging genetics of schizophrenia. Dialogues Clin Neurosci 12:449–456

    PubMed Central  PubMed  Google Scholar 

  • Mizoguchi K, Shoji H, Tanaka Y, Maruyama W, Tabira T (2009) Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats. Neuroscience 162:1192–1201

    Article  CAS  PubMed  Google Scholar 

  • Motulsky HJ (2010) Intuitive biostatistics: A nonmathematical guide to statistical thinking. Oxford University Press, New York

    Google Scholar 

  • Motulsky HJ, Brown RE (2006) Detecting outliers when fitting data with nonlinear regression-a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7:123

    Article  PubMed Central  PubMed  Google Scholar 

  • Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH (2004) Expression of ionotropic gluatamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121:60–69

    Article  CAS  PubMed  Google Scholar 

  • Nasrallah H, Tandon R, Keshavan M (2011) Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci 20:317–327

    Article  CAS  PubMed  Google Scholar 

  • Nelander J, Hebsgaard JB, Parmar M (2009) Organization of the human embryonic ventral mesencephalon. Gene Expr Patterns 9:555–561

    Article  CAS  PubMed  Google Scholar 

  • Nieuwenhuys R, Voogd J, van Huijzen C (2008) Topography of spinal cord, brain stem and cerebellum. In: Nieuwenhuys R, Voogd J, van Huijzen C (eds) The human central nervous system. Springer, Berlin, pp 177–246

    Chapter  Google Scholar 

  • Paxinos G, Huang XF (1995) Atlas of the human brainstem. Academic Press, San Diego

    Google Scholar 

  • Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113:287–302

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC (2012a) Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry 3:31

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Perez-Costas E, Rodriguez-Pallares J, Roberts RC, Labandeira-Garcia JL, Melendez-Ferro M (2012b) Poly-c-binding proteins in schizophrenia: a possible mechanism for tyrosine hydroxylase pathology. Program No. 452.11. 2012. Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2012

  • Puelles L, Verney C (1998) Early neuromeric distribution of tyrosine-hydroxylase-immunoreactive neurons in human embryos. J Comp Neurol 394:283–308

    Article  CAS  PubMed  Google Scholar 

  • Raznahan A, Greenstein D, Lee Y, Long R, Clasen L, Gochman P, Addington A, Giedd JN, Rapoport JL, Gogtay N (2011) Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls. Neuroimage 57:1517–1523

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Remington G, Agid O, Foussias G (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev Neurother 11:589–607

    Article  CAS  PubMed  Google Scholar 

  • Rice MW, Smith KL, Roberts RC, Perez-Costas E, Melendez-Ferro M (2014) Assessment of cytochrome c oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia. PLoS One 9(6):e100054. doi:10.1371/journal.pone.0100054

  • Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC (2008) Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol 115:461–470

    Article  PubMed Central  PubMed  Google Scholar 

  • Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1–58

    Article  CAS  PubMed  Google Scholar 

  • Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152

    Article  CAS  PubMed  Google Scholar 

  • Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219

    Article  CAS  PubMed  Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719

    Article  CAS  PubMed  Google Scholar 

  • Smidt MP, Burbach JP (2007) How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8:21–32

    Article  CAS  PubMed  Google Scholar 

  • Smits SM, Burbach JP, Smidt MP (2006) Developmental origin and fate of meso-diencephalic dopamine neurons. Prog Neurobiol 78:1–16

    Article  CAS  PubMed  Google Scholar 

  • Smits SM, von Oerthel L, Hoekstra EJ, Burbach JP, Smidt MP (2013) Molecular marker differences relate to developmental position and subsets of meso-diencephalic dopaminergic neurons. PLoS One 8(10):e76037

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Spitzer RL, Williams JB, Gibbon M, First MB (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 49:624–629

    Article  CAS  PubMed  Google Scholar 

  • Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2010) What causes the death of dopaminergic neurons in Parkinson’s disease? Prog Brain Res 183:59–77

    Article  CAS  PubMed  Google Scholar 

  • Tan HY, Callicott JH, Weinberger DR (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17:171–181

    Article  Google Scholar 

  • Tanaka S (2006) Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. Neuroscience 139:153–171

    Article  CAS  PubMed  Google Scholar 

  • Thuret S, Bhatt L, O’Leary DD, Simon HH (2004) Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Mol Cell Neurosci 25:394–405

    Article  CAS  PubMed  Google Scholar 

  • Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336

    Article  PubMed  Google Scholar 

  • Tost H, Hakimi S, Meyer-Lindenberg A (2010) Dopamine dysfunction in schizophrenia: from genetic susceptibility to cognitive impairment. In: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A (eds) Dopamine Handbook. Oxford University Press, Oxford, pp 558–571

    Google Scholar 

  • van den Heuvel DM, Pasterkamp RJ (2008) Getting connected in the dopamine system. Prog Neurobiol 85:75–93

    Article  PubMed  Google Scholar 

  • van Domburg PH, ten Donkelaar HJ (1991) The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases. Adv Anat Embryol Cell Biol 121:1–132

    Article  PubMed  Google Scholar 

  • van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645

    PubMed  Google Scholar 

  • Verney C (1999) Distribution of the catecholaminergic neurons in the central nervous system of human embryos and fetuses. Microsc Res Tech 46:24–47

    Article  CAS  PubMed  Google Scholar 

  • Verney C, Zecevic N, Puelles L (2001) Structure of longitudinal brain zones that provide the origin for the substantia nigra and ventral tegmental area in human embryos, as revealed by cytoarchitecture and tyrosine hydroxylase, calretinin, calbindin and GABA immunoreactions. J Comp Neurol 429:22–44

    Article  CAS  PubMed  Google Scholar 

  • Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 7:155–159

    Article  CAS  PubMed  Google Scholar 

  • Williams MR, Galvin K, O’Sullivan B, Macdonald CD, Ching EW, Turkheimer F, Howes OD, Pearce RK, Hirsch SR and Maier M (2013) Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci (In press)

  • Winter S, Dieckmann M, Schwabe K (2009) Dopamine in the prefrontal cortex regulates rats behavioral flexibility to changing reward value. Behav Brain Res 198:206–213

    Article  CAS  PubMed  Google Scholar 

  • Zecevic N, Verney C (1995) Development of the catecholamine neurons in human embryos and fetuses, with special emphasis on the innervation of the cerebral cortex. J Comp Neurol 351:509–535

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank the Maryland Brain Collection, University of Maryland School of Medicine for providing the samples used in this study. This work was supported by the National Institutes of Health (USA) grant R01MH066123-09 awarded to MMF, EPC and RCR.

Conflict of interest

The authors do not have any conflict of interest to report.

Ethical standards

The manuscript does not contain clinical studies or patient data.

Author information

Authors and Affiliations

  1. Department of Psychology, University of Alabama at Birmingham, Campbell Hall 415, 1720 2nd Avenue South, Birmingham, AL, 35294, USA

    Matthew W. Rice, Miguel Melendez-Ferro & Emma Perez-Costas

  2. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, USA

    Rosalinda C. Roberts, Miguel Melendez-Ferro & Emma Perez-Costas

Authors
  1. Matthew W. Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosalinda C. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Melendez-Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emma Perez-Costas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma Perez-Costas.

Additional information

M. Melendez-Ferro and E. Perez-Costas are equal contributors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rice, M.W., Roberts, R.C., Melendez-Ferro, M. et al. Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 221, 185–201 (2016). https://doi.org/10.1007/s00429-014-0901-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00429-014-0901-y

Keywords

Search

Navigation